SynthesisThe Cochrane database of systematic reviews2014
First-line beta-blockers versus other antihypertensive medications for chronic type B aortic dissection.
Synthesis in The Cochrane database of systematic reviews, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 35 citations in OpenAlex.
- Response to dual anti-impulse and lipid-lowering therapy is associated with clinical outcomes in chronic type B aortic syndrome.Internal and emergency medicine · 2026Observational
- Clinical features of pregnancy-associated aortic dissection and pregnancy outcomes.BMC pregnancy and childbirth · 2026Article
- A rare case of Takayasu arteritis with aortic dissection in a young male patient presented with hypertensive urgency.Annals of medicine and surgery (2012) · 2025Article
- Management of hypertensive crisis: British and Irish Hypertension Society Position document.Journal of human hypertension · 2023Review
- Multi-omics in thoracic aortic aneurysm: the complex road to the simplification.Cell & bioscience · 2023Review
- Pharmacological treatment in patients with aortic dissection.Open heart · 2022Article
- Use of Anti-Thrombotic Drugs and In-Hospital Mortality in Acute Aortic Dissection Patients.Diagnostics (Basel, Switzerland) · 2022Article
- Optimal blood pressure control for patients after thoracic endovascular aortic repair of type B aortic dissection.BMC cardiovascular disorders · 2019Article
- Engaging patients and caregivers in establishing research priorities for aortic dissection.SAGE open medicine · 2019Article
- Challenging Current Conservative Management of Uncomplicated Acute Type B Aortic Dissections.EJVES short reports · 2018Article
- Acute Aortic Syndromes: Update in Current Medical Management.Current treatment options in cardiovascular medicine · 2017Review
- Molecular pathogenesis of genetic and sporadic aortic aneurysms and dissections.Current problems in surgery · 2017Review
- Epidemiology and Medication Utilization Pattern of Aortic Dissection in Taiwan: A Population-Based Study.Medicine · 2015Observational
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThoracic aortic dissection (TAD) is a severe and often lethal complication in people with hypertension. Current practice in the treatment of chronic type B aortic dissections is the use of beta-blockers as first-line therapy to decrease aortic wall stress. Other antihypertensive medications, such as calcium channel blockers (CCBs), angiotensin-converting enzyme (ACE) inhibitors or angiotensin II receptor blockers (ARBs), have been suggested for the medical therapy of type B TAD.
objectivesTo assess the effects of first-line beta-blockers compared with other first-line antihypertensive drug classes for treating chronic type B TAD. SEARCH
methodsWe searched the Database of Abstracts of Reviews of Effects (DARE) for related reviews. We searched the Hypertension Group Specialised Register (1946 to 26 January 2014), the Cochrane Central Register of Controlled Trials (2014, Issue 1), MEDLINE (1946 to 24 January 2014), MEDLINE In-Process, EMBASE (1974 to 24 January 2014) and ClinicalTrials.gov (to 26 January 2014). SELECTION CRITERIA: We considered randomized controlled trials (RCTs) comparing different antihypertensive medications in the treatment of chronic type B TAD to be eligible for inclusion. Total mortality rate was the primary outcome of this review. Secondary outcomes included total non-fatal adverse events relating to TADs and number of people not requiring surgical treatment. DATA COLLECTION AND ANALYSIS: Two review authors (KC, PL) independently reviewed titles and abstracts and decided on studies to include based on the inclusion criteria. We resolved discrepancies between the two review authors by discussion. MAIN
resultsAfter a thorough review of the search results, we identified no studies that met the inclusion criteria. AUTHORS'
conclusionsWe did not find any RCTs that compared first-line beta-blockers with other first-line antihypertensive medications for the treatment of chronic type B TAD. Therefore, there is no RCT evidence to support the current guidelines recommending the use of beta-blockers. RCTs are required to assess the benefits and harms of beta-blockers and other antihypertensive medications as first-line treatment of chronic type B TAD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.